Solid Biosciences Inc. [NASDAQ: SLDB] price plunged by -20.99 percent to reach at -$1.78. The company report on January 6, 2021 that Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20 am ET. Following the prepared remarks, several members of the leadership team will be available for Q&A.
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.
A sum of 3898581 shares traded at recent session while its average daily volume was at 1.91M shares. Solid Biosciences Inc. shares reached a high of $8.18 and dropped to a low of $6.51 until finishing in the latest session at $6.70.
The one-year SLDB stock forecast points to a potential downside of -17.54. The average equity rating for SLDB stock is currently 3.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Solid Biosciences Inc. [SLDB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLDB shares is $5.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLDB stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Solid Biosciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 08, 2021. The new note on the price target was released on July 28, 2020, representing the official price target for Solid Biosciences Inc. stock.
The Average True Range (ATR) for Solid Biosciences Inc. is set at 0.84 The Price to Book ratio for the last quarter was 14.57, with the Price to Cash per share for the same quarter was set at 0.32.
SLDB Stock Performance Analysis:
Solid Biosciences Inc. [SLDB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.61. With this latest performance, SLDB shares gained by 82.07% in over the last four-week period, additionally plugging by 127.89% over the last 6 months – not to mention a rise of 76.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLDB stock in for the last two-week period is set at 53.62, with the RSI for the last a single of trading hit 48.88, and the three-weeks RSI is set at 56.23 for Solid Biosciences Inc. [SLDB]. The present Moving Average for the last 50 days of trading for this stock 4.69, while it was recorded at 7.51 for the last single week of trading, and 3.27 for the last 200 days.
Insight into Solid Biosciences Inc. Fundamentals:
Return on Total Capital for SLDB is now -111.86, given the latest momentum, and Return on Invested Capital for the company is -110.99. Return on Equity for this stock declined to -114.24, with Return on Assets sitting at -96.45. When it comes to the capital structure of this company, Solid Biosciences Inc. [SLDB] has a Total Debt to Total Equity ratio set at 8.83. Additionally, SLDB Total Debt to Total Capital is recorded at 8.11, with Total Debt to Total Assets ending up at 6.83. Long-Term Debt to Equity for the company is recorded at 6.43, with the Long-Term Debt to Total Capital now at 5.91.
Reflecting on the efficiency of the workforce at the company, Solid Biosciences Inc. [SLDB] managed to generate an average of -$968,785 per employee.Solid Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.
SLDB Stock EPS
With the latest financial reports released by the company, Solid Biosciences Inc. posted -0.65/share EPS, while the average EPS was predicted by analysts to be reported at -0.61/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -6.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLDB.
Solid Biosciences Inc. [SLDB] Insider Position Details
There are presently around $173 million, or 67.40% of SLDB stock, in the hands of institutional investors. The top three institutional holders of SLDB stocks are: PERCEPTIVE ADVISORS LLC with ownership of 6,749,803, which is approximately 0% of the company’s market cap and around 23.60% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 4,571,164 shares of the stock with an approximate value of $30.63 million in SLDB stocks shares; and BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, currently with $25.94 million in SLDB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Solid Biosciences Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 24 institutional holders increased their position in Solid Biosciences Inc. [NASDAQ:SLDB] by around 483,762 shares. Additionally, 35 investors decreased positions by around 1,442,542 shares, while 14 investors held positions by with 23,897,653 shares. The mentioned changes placed institutional holdings at 25,823,957 shares, according to the latest SEC report filing. SLDB stock had 7 new institutional investments in for a total of 158,954 shares, while 11 institutional investors sold positions of 223,526 shares during the same period.